Biologics and Conjugates CDMO Services

Dual-Payload Conjugates: Addressing the CMC Challenges of a New Therapeutic Approach

Dual-payload conjugates—two mechanistically distinct payloads carried on a single targeting vehicle—represent the next technological frontier beyond conventional ADCs.

More

PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities

This article offers a systematic overview of PMO drug technology covering underlying principles, manufacturing workflows, and therapeutic prospects.

More

Mechanistic Studies in Catalytic Process Development: Supporting Manufacturing Processes and Revealing New Reaction Pathways

Through a case study on loading-dependent chemoselectivity in amide reductions, we demonstrate how first-principles chemical understanding provides the scientific foundation necessary for robust, end-to-end commercial manufacturing control strategies

More

Antibody-Oligonucleotide Conjugates: From Conjugation Strategy to Purification and Analytical Control

Antibody-Oligo Conjugate (AOC), as an innovative targeted gene therapy biopharmaceutical, effectively integrates the targeting advantages of monoclonal antibodies and the gene regulatory functions of oligonucleotides, helping address key limitations in the inherent of traditional antibody drugs and nucleic acid drugs, and showing substantial clinical

More

FAQ: CMC Development Strategy for Oligonucleotides in AOCs

•How to reduce hydrolysis during SMCC conjugation? •Can SMCC conjugate after hydrolytic ring-opening? •How is OAR1 regulated during random SMCC conjugation? •Which strategy is preferred for siRNA linker conjugation: pre-annealing or post-annealing conjugation?

More

Biocatalysis Enables the Efficient Synthesis and Commercial Application of Unnatural Amino Acids (UAAs)

Biocatalysis is a pivotal enabler for the sustainable synthesis of unnatural amino acids. By integrating novel enzyme discovery, multi-enzyme cascades and chemo-enzymatic routes, Porton has established practical capabilities to address industry challenges in substrate specificity and enzyme stability. Moving forward, Porton remains dedicated to bridging the gap between laboratory innovation and industrial-scale application, providing customers with reliable, scalable and atom-efficient solutions for UAA production.

More

Dry Particle Coating for the Enhancement of API Flowability and Bulk Density

The mechanism of the dry particle coating and a short description of four coating techniques including comil, LabRAM, a high shear mixer and a jet mill are provided.

More

Process Development and Quality Research Strategy for Dual-Payload Conjugated Drugs

What is the mainstream conjugation process for antibodies and siRNA?

More

FAQ: Process Development Strategies for AOC Drugs

What is the mainstream conjugation process for antibodies and siRNA?

More

Optimization of Synthetic Process and Metal-Chelation Impurity Control Strategy for Complex Peptide-based RDCs

It fully demonstrates the strength of Porton's one-stop RDC service platform, excellent project management capabilities, and efficient production and operation.

More

The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology

Adhering to Porton's core value of “Pursuing Excellence”, the Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.

More

Process Simulation Platform: Enabling Process Development and Scale-up of Active Pharmaceutical Ingredients

The Porton Crystallization team has the capability to perform process simulation of unit operations, including solvent swap, crystallization, filtration and drying.

More